NALIA's multiplex immunoassay technology is ideal for use in oncology research
Research in oncology requires analysis of multiple biomarkers, but availability of sample can often be limiting. NALIA's mutiplex biomarker panels provide accurate information on many biomarkers whilst sparing sample.
It is clear that for most cancers there is no single marker that can confirm diagnosis, indicate prognosis or predict response to a particular therapy. Instead, many different markers must be analysed.
This is an ideal application for NALIA technology and the company is seeking partnerships with groups that have specific cancer biomarker panels. We can develop customised multiplex panels containing both public domain and partners' proprietary markers to provide a research tool, a tool for validating biomarkers and, ultimately, a diagnostic system.